Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 48

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 48
---
 of the stated value thereof divided by a conversion price of $5.82; (iv) Series A Warrants
to purchase 6,135 shares of Common Stock at an exercise price of $139.00 per share; (v) initial
Series C Warrants to purchase 81,753 shares of Common Stock at an exercise price of $9.80;
(vi) December 2024 and January 2025 Common Warrants to purchase an aggregate of 247,914 shares
of Common Stock at an exercise price ranging from $5.61 to $5.82, and (vii) Public Warrants
and Private Placement Warrants to purchase an aggregate of 95,186 shares of Common Stock
at exercise prices ranging from $920.00 to $1,150.00 per share.

Although each of the conversion
price of the Preferred Shares and the exercise price of the Series A Preferred Warrants are at or above the trading price of our Common
Stock as of the date of this prospectus, if such trading price increases, such conversion prices and exercise price will not change as
a result thereof and could be below the trading price of our Common Stock as of the date of any future conversion or exercise thereof,
resulting in dilution to our stockholders. In addition, the terms of the Series A Preferred Stock, the Series B Preferred Stock and the
Series C Preferred Stock contain certain penalties and adjustments to the amount included in determination of the conversion rate following
certain breaches of the Company’s obligations thereunder, including, among other things, as a result of a failure to file or cause
the SEC to declare one or more registration statements relating to the resale of the shares of Common Stock issuable upon conversion
thereof by specified deadlines, certain defaults under indebtedness of the Company or judgments against the Company and failure to deliver
shares of Common Stock upon conversion in a timely manner. For example, the penalties and adjustments include a 25% premium added to
the stated value for determining the conversion rate in connection with breaches other than the breach of the requirement to redeem the
shares of Series A Preferred Stock and Series B Preferred Stock by August 14, 2025, which results in a 50% premium, and the addition
to the stated value of an amount equal to the value of the shares of Common Stock into which the Series A Preferred Stock or Series B
Preferred Stock would have been convertible if the conversion price were equal to 80% of the lowest volume weighted